Polyrizon Ltd. Announces $3.5 Million Registered Direct Offering and Private Placement

Rhea-AI Summary

Polyrizon (NASDAQ: PLRZ) announced a registered direct offering and concurrent private placement expected to raise approximately $3.5 million. The transactions include 388,888 Units or Pre-Funded Units at $9.00 each and warrants exercisable at $9.00 per share.

Closing is expected on or about April 8, 2026, subject to customary conditions; Aegis Capital is acting as exclusive placement agent.

Positive

• $3.5M gross proceeds expected from combined offerings
• Pre-funded warrants are immediately exercisable (registered ones)
• Registration rights granted to permit future resale
• Aegis Capital engaged as exclusive placement agent

Negative

• Potential share dilution to 2,083,939 shares if exercised
• Majority of securities sold in a private placement restricting resale
• Financing placed with a single institutional investor, concentration risk

News Market Reaction – PLRZ

-9.92%

5 alerts

-9.92% Session close to close

+7.0% Peak Tracked

-8.7% Trough Tracked

$19.95M Market Cap

0.6x Rel. Volume

In the Apr 7 session, PLRZ declined 9.92%, reflecting a notable negative market reaction. Argus tracked a peak move of +7.0% during that session. Argus tracked a trough of -8.7% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -9.9% in the session following this news. A negative reaction despite the capital ra...

Analysis

The stock moved -9.9% in the session following this news. A negative reaction despite the capital raise fits a pattern where recent Polyrizon updates have been followed by selling, even when operationally positive. The offering brings in about $3.5 million but adds shares and warrants on top of a $50,000,000 shelf, highlighting dilution concerns. Investors may also weigh ongoing operating losses of $6.249 million in 2025 and recent insider selling when reassessing valuation.

Key Figures

Gross proceeds: $3.5 million Units sold: 388,888 Units Unit offering price: $9.00 per Unit +5 more

8 metrics

Gross proceeds $3.5 million Aggregate expected from registered direct offering and private placement

Units sold 388,888 Units Each Unit/Pre-Funded Unit includes 1 share (or pre-funded warrant) and 1 common warrant

Unit offering price $9.00 per Unit Combined price for Ordinary Share and Common Warrant

Pre-Funded Unit price $8.99999 per Pre-Funded Unit Equal to Unit price minus $0.00001 pre-funded warrant exercise

Pre-Funded Warrant exercise $0.00001 per warrant Exercise price for each Pre-Funded Warrant

Post-offering shares 2,083,939 Ordinary Shares Assumes exercise of all Pre-Funded and PIPE Pre-Funded Warrants

Shelf capacity $50,000,000 Maximum aggregate amount under Form F-3 shelf registration

2025 operating loss $6.249 million Operating loss for year ended December 31, 2025 (Form 20-F)

Historical Context

5 past events · Latest: Mar 26 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 26	Corporate highlights	Positive	-3.4%	Year-end cash update and multiple preclinical and regulatory milestones.
Mar 25	Annual report filing	Neutral	-3.4%	Form 20-F filing providing full-year 2025 financials and disclosures.
Mar 24	Acquisition intent	Positive	-5.0%	Non-binding MOU to buy up to 20% of eVTOL developer Colugo.
Mar 17	Preclinical CRO deal	Positive	-4.2%	Agreement with global preclinical CRO for ISO 10993 GLP studies.
Mar 10	GMP CTM milestone	Positive	-0.1%	Successful GMP batch of clinical trial material for planned U.S. study.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent operational and filings news, generally positive or neutral in tone, has repeatedly coincided with negative next‑day price moves.

Recent Company History

Over the last month, Polyrizon released several updates: positive preclinical and regulatory progress, a CRO agreement for GLP biocompatibility studies starting in Q2 2026, and GMP manufacturing of clinical trial material. It also filed its 2025 Form 20‑F and an amendment, and announced a non‑binding MOU to acquire up to a 20% stake in Colugo for up to $6,000,000. Despite generally constructive developments, all five tracked announcements saw negative 24‑hour price reactions, highlighting a pattern of selling into news.

Key Terms

registered direct offering, private placement, pre-funded warrants, common warrant, +3 more

7 terms

registered direct offering financial

"definitive agreements with a single institutional investor for the purchase and sale of its Ordinary Shares and pre-funded warrants in a registered direct offering."

A registered direct offering is a way for a company to sell new shares of its stock directly to select investors with regulatory approval. This method allows the company to raise funds quickly and efficiently without needing a public auction, similar to offering exclusive access to a limited number of buyers. For investors, it often provides an opportunity to purchase shares at a favorable price, while giving the company immediate access to capital.

private placement financial

"In a concurrent private placement, the Company also agreed to sell to the same investor pre-funded and investor warrants."

A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.

pre-funded warrants financial

"purchase and sale of its Ordinary Shares and pre-funded warrants in a registered direct offering."

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

common warrant financial

"each consisting of one (1) Ordinary Share ... and one (1) Common Warrant to purchase one (1) Ordinary Share"

A common warrant is a tradable security that gives its holder the right to buy a company’s common shares at a preset price for a limited time. It matters to investors because exercising warrants can dilute existing ownership and create leverage: holders can benefit if the stock rises above the preset price, while holders of original shares face potential reduction in their percentage stake, similar to more tickets being added to a raffle.

shelf registration statement regulatory

"The registered direct offering is being made pursuant to an effective shelf registration statement on Form F-3 (No. 333-291368)"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

form f-3 regulatory

"effective shelf registration statement on Form F-3 (No. 333-291368) previously filed with the U.S. Securities and Exchange Commission"

Form F-3 is a U.S. securities filing that lets eligible foreign companies pre-register and then quickly sell shares or other securities to raise money, because they already meet ongoing reporting and size tests. For investors it signals that the company is up-to-date with regulatory disclosure and has an efficient way to issue new securities — similar to a pre-approved credit line — which can mean faster capital raises but also potential dilution of existing holdings.

accredited investors financial

"The securities were offered only to accredited investors."

Accredited investors are individuals or entities considered to have enough financial knowledge and resources to understand and handle more complex and risky investments. They are often allowed to participate in private investment opportunities that are not available to the general public, similar to how experienced players might access exclusive clubs or events. This status helps ensure that investors can manage potential risks and rewards appropriately.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

RAANANA, ISRAEL, April 07, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ: PLRZ) (the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today announced that it has entered into definitive agreements with a single institutional investor for the purchase and sale of its Ordinary Shares and pre-funded warrants in a registered direct offering. In a concurrent private placement, the Company also agreed to sell to the same investor pre-funded and investor warrants. Aggregate gross proceeds to the Company from both transactions are expected to be approximately $3.5 million.

The transactions consisted of the sale of 388,888 Units (or Pre-Funded Units), each consisting of one (1) Ordinary Share (or one (1) Pre-Funded Warrant to purchase one (1) Ordinary Share) and one (1) Common Warrant to purchase one (1) Ordinary Share, at a combined offering price of $9.00 per Unit (or $8.99999 per Pre-Funded Unit, equal to the offering price per Unit minus an exercise price of $0.00001 per Pre-Funded Warrant). In the registered direct offering, the Company agreed to sell 87,777 Ordinary Shares and 190,000 Pre-Funded Warrants. In the concurrent private placement, the Company agreed to sell 111,111 PIPE Pre-Funded Warrants and 388,888 PIPE Common Warrants. The Pre-Funded Warrants will be immediately exercisable (subject to registration for unregistered PIPE Pre-Funded Warrants) and may be exercised at any time until exercised in full. The Common Warrants have an exercise price of $9.00 per share. For each Pre-Funded Warrant sold in lieu of an Ordinary Share, the number of Ordinary Shares offered will be decreased on a one-for-one basis.

The transactions are expected to close on or about April 8, 2026, subject to the satisfaction of customary closing conditions. The Company expects to use the net proceeds from the offerings, together with its existing cash, for general corporate purposes and working capital. Following completion of the offering, the Company will have 2,083,939 Ordinary Shares issued and outstanding, assuming the exercise of all Pre-Funded Warrants and PIPE Pre-Funded Warrants issued in the offering.

Aegis Capital Corp. is acting as exclusive placement agent for the offerings. Greenberg Traurig, P.A. is acting as U.S. counsel to the Company and Meitar | Law Offices is acting as Israeli counsel to the Company. Kaufman & Canoles, P.C. is acting as counsel to Aegis Capital Corp.

The registered direct offering is being made pursuant to an effective shelf registration statement on Form F-3 (No. 333-291368) previously filed with the U.S. Securities and Exchange Commission (SEC) and declared effective by the SEC on December 3, 2025. A final prospectus supplement and accompanying prospectus describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC’s website located at www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying prospectus may be obtained, when available, by contacting Aegis Capital Corp., Attention: Syndicate Department, 1345 Avenue of the Americas, 27th floor, New York, NY 10105, by email at syndicate@aegiscap.com, or by telephone at +1 (212) 813-1010.

The offer and sale of the securities in the private placement are being made in a transaction not involving a public offering and have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or applicable state securities laws. Accordingly, the securities may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. The securities were offered only to accredited investors. Pursuant to a registration rights agreement with the investors, the Company has agreed to file one or more registration statements with the SEC covering the resale of the Ordinary Shares and the Shares issuable upon exercise of the pre-funded warrants and warrants.

Interested parties should read in their entirety the prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in such prospectus supplement and the accompanying prospectus, which provide more information about the Company and such offering.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Polyrizon Ltd.

Polyrizon is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Polyrizon’s proprietary Capture and Contain TM, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a “biological mask” with a thin shield containment barrier in the nasal cavity. Polyrizon is further developing certain aspects of its C&C hydrogel technology such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs. Polyrizon refers to its additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap and Target ™, or T&T. For more information, please visit https://polyrizon-biotech.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the timing and completion of the offering, the satisfaction of customary closing conditions related to the offering and the intended use of proceeds therefrom. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report filed with the SEC on March 25, 2026 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Polyrizon is not responsible for the contents of third-party websites.

Michal Efraty
Investor Relations
IR@polyrizon-biotech.com

FAQ

What financing did Polyrizon (PLRZ) announce on April 7, 2026?

Polyrizon announced a registered direct offering and private placement expected to raise about $3.5 million. According to the company, the transactions include Units, pre-funded warrants and common warrants priced at $9.00 per Unit.

How many Units and warrants did Polyrizon (PLRZ) agree to sell in the offering?

The company agreed to sell a total of 388,888 Units or Pre-Funded Units and associated warrants. According to the company, the deal also includes specified registered and PIPE pre-funded warrants and PIPE common warrants.

When will the Polyrizon (PLRZ) offering close and who is the placement agent?

The transactions are expected to close on or about April 8, 2026, subject to customary closing conditions. According to the company, Aegis Capital is acting as exclusive placement agent for the offerings.

What is the exercise price and exercisability of the Polyrizon (PLRZ) warrants?

Common warrants issued in the transactions have an exercise price of $9.00 per share. According to the company, the pre-funded warrants are immediately exercisable, subject to registration for unregistered PIPE pre-funded warrants.

How will the offering affect Polyrizon's (PLRZ) outstanding share count?

Assuming exercise of all pre-funded warrants sold, Polyrizon would have 2,083,939 ordinary shares issued and outstanding. According to the company, that figure reflects full exercise of pre-funded warrants issued in the offering.